SGD Pharma announced the opening of a new siliconization operation at its Saint-Quentin Lamotte (SQLM) plant. The company enhances its range of in-house services by internalizing its glass siliconization offer, ensuring increased responsiveness, security of supply and improved flexibility of vial sizes.